US.REGN · Regeneron Pharmaceuticals

{
  "risk": {
    "level": "Medium",
    "reason": "risk management score >= 6.5/10",
    "position": {
      "score": 1.6,
      "details": {
        "atrPct": 2.6244770519924474,
        "turnoverUsdM": 447.56662539999996,
        "liquidityPoints": 0.6,
        "volatilityPoints": 1
      }
    },
    "rrPoints": 1.4,
    "stopLevels": {
      "symbol": "US.REGN",
      "rr_range": "1:1.0-1:2.5",
      "risk_profile": "中等",
      "stop_loss_price": 767.7772,
      "strength_details": {
        "ma_score": 1.5,
        "atr_score": 2,
        "rsi_score": 2,
        "macd_score": 1.5,
        "volume_score": 1
      },
      "market_adjustment": 1,
      "risk_reward_ratio": 1,
      "stop_loss_percent": 5.2,
      "take_profit_price": 852.7365,
      "target_multiplier": 1.9,
      "technical_strength": 1.58,
      "take_profit_percent": 5.2
    },
    "positionPoints": 1.6,
    "stopLossPoints": 1.8,
    "diversification": {
      "score": 2,
      "details": {
        "method": "sector concentration proxy; no portfolio holdings used",
        "sector": "Health Care",
        "concentratedSectorPenalty": 0
      }
    },
    "riskRewardRatio": 1.2,
    "stopLossPercent": 5.248954103984895,
    "diversificationPoints": 2
  },
  "total": {
    "max": 160,
    "result": 61.1,
    "formula": "score_with_momentum_v2 = main_score + momentum_5d_v2_score",
    "baseScore": 54.1,
    "modelVersion": "cursor_18_27_news_v2_160",
    "momentum5dScore": 7
  },
  "market": {
    "ma20": 817.8655,
    "ma50": 741.4102,
    "close": 810.31,
    "prevClose": 827.72,
    "avgVolume20": 652817,
    "volumeRatio": 0.85,
    "changePercent": -2.1
  },
  "sources": {
    "catalyst": "finnhub_news_keyword_model",
    "sentiment": "finnhub_news_keyword_model",
    "fundamentals": "fmp_stable",
    "institutional": null,
    "marketContext": "twelvedata+fred"
  },
  "barCount": 60,
  "momentum": {
    "max": 50,
    "result": 7,
    "details": {
      "ret_5d": 0.014053640137518197,
      "max_score": 50,
      "max_total": 50,
      "raw_total": 7,
      "vcp_bonus": 0,
      "vol_ratio": 0.8052953483455682,
      "ret_points": 4,
      "vol_points": 0,
      "range_ratio": 1.1323862085158518,
      "volat_points": 0,
      "day_range_pct": 0.026841579148720863,
      "model_version": "cursor_18_27_news_v2_160",
      "available_bars": 30,
      "breakout_points": 0,
      "partial_history": false,
      "pullback_points": 3,
      "breakout_vol_bonus": 0,
      "first_breakout_20d": false,
      "return_window_days": 5,
      "first_breakout_bonus": 0,
      "breakout_quality_points": 0
    },
    "formula": "Cursor_18.25 5D momentum v2 0-50",
    "modelVersion": "cursor_18_27_news_v2_160"
  },
  "scoreMax": 110,
  "composite": {
    "max": 160,
    "result": 61.1,
    "formula": "Cursor_18.25 ranking score v2 (score_with_momentum_v2)",
    "weights": [
      {
        "raw": 3.9,
        "label": "基本面",
        "weight": "5/110",
        "normalized": 78,
        "contribution": 3.9
      },
      {
        "raw": 6.8,
        "label": "資金流",
        "weight": "20/110",
        "normalized": 34,
        "contribution": 6.8
      },
      {
        "raw": 10.4,
        "label": "市場環境",
        "weight": "15/110",
        "normalized": 69.33,
        "contribution": 10.4
      },
      {
        "raw": 6,
        "label": "催化劑",
        "weight": "20/110",
        "normalized": 30,
        "contribution": 6
      },
      {
        "raw": 6.8,
        "label": "風險管理",
        "weight": "10/110",
        "normalized": 68,
        "contribution": 6.8
      },
      {
        "raw": 18.3,
        "label": "技術信號",
        "weight": "30/110",
        "normalized": 61,
        "contribution": 18.3
      },
      {
        "raw": 2,
        "label": "情緒分析",
        "weight": "10/110",
        "normalized": 20,
        "contribution": 2
      }
    ],
    "modelVersion": "cursor_18_27_news_v2_160"
  },
  "momentumMax": 50,
  "scoreStatus": "checked",
  "standard110": {
    "rating": "避免",
    "result": 54.1,
    "details": [
      "基本面分析總分: 3.9/5分",
      "資金流分析總分: 6.8/20分",
      "市場環境分析總分: 10.4/15分",
      "催化劑分析: 6/20分",
      "風險管理總分: 6.8/10分",
      "技術信號分析總分: 18.3/30分",
      "情緒分析: 2/10分",
      "共振率(僅顯示不加分): 0%"
    ],
    "formula": "基本面5 + 資金流20 + 市場環境15 + 催化劑20 + 風險管理10 + 技術信號30 + 情緒10",
    "dimensionScores": {
      "催化劑": 6,
      "基本面": 3.9,
      "資金流": 6.8,
      "市場環境": 10.4,
      "情緒分析": 2,
      "技術信號": 18.3,
      "風險管理": 6.8
    },
    "dimensionDetails": {
      "催化劑": {
        "max": 20,
        "grade": "較差",
        "items": {
          "catalyst": {
            "score": 6,
            "details": {
              "source": "finnhub_news_keyword_model",
              "articleCount": 8,
              "catalystCount": 1
            }
          },
          "catalystPoints": 6
        }
      },
      "基本面": {
        "max": 5,
        "grade": "良好",
        "items": {
          "pbPoints": 0.4,
          "pePoints": 0.5,
          "epsPoints": 0,
          "roePoints": 0.4,
          "debtPoints": 0.5,
          "marginPoints": 0.75,
          "turnoverUsdM": 447.56662539999996,
          "volumePoints": 0.5,
          "revenuePoints": 0,
          "dividendPoints": 0.3,
          "marketCapPoints": 0.5
        },
        "source": "fmp_stable"
      },
      "資金流": {
        "max": 20,
        "grade": "較差",
        "items": {
          "cmfPoints": 0.8,
          "mfiPoints": 1.6,
          "obvPoints": 1.6,
          "vwapPoints": 0.8,
          "institutional": {
            "score": 2,
            "details": {
              "source": "optional-neutral",
              "warning": {
                "code": "INSTITUTIONAL_DATA_OPTIONAL",
                "symbol": "US.REGN",
                "message": "Institutional ownership is unavailable; neutral 2/4 money-flow treatment used."
              },
              "optional": true,
              "holderCount": null,
              "holderPoints": 2,
              "top10ShareRatio": null,
              "concentrationPenalty": 0
            }
          },
          "institutionPoints": 2
        }
      },
      "市場環境": {
        "max": 15,
        "grade": "一般",
        "items": {
          "vix": {
            "score": 2.4,
            "details": {
              "source": "twelvedata+fred",
              "vixClose": 15.3
            }
          },
          "trend": {
            "score": 3.4,
            "details": {
              "qqq": {
                "ma20": 717.3850005500001,
                "ma50": 711.3217994399997,
                "name": "QQQ",
                "close": 718.35999,
                "points": 2
              },
              "spy": {
                "ma20": 768.6994929500001,
                "ma50": 757.5966012200001,
                "name": "SPY",
                "close": 765.96002,
                "points": 1.4
              },
              "source": "twelvedata+fred"
            }
          },
          "atrPct": 2.6244770519924474,
          "atrPoints": 3,
          "cciPoints": 1.6,
          "vixPoints": 2.4,
          "marketTrendPoints": 3.4
        }
      },
      "情緒分析": {
        "max": 10,
        "grade": "較差",
        "items": {
          "sentiment": {
            "score": 2,
            "details": {
              "source": "finnhub_news_keyword_model",
              "articleCount": 8,
              "negativeHits": 0,
              "positiveHits": 0,
              "sentimentScoreRaw": 0
            }
          },
          "sentimentData": {
            "raw": [
              {
                "id": 141950848,
                "url": "https://finnhub.io/api/news?id=025ab8bb5b52548fe73e84956d901e99f64b8a2d0c299eba6338137c0b522450",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "REGN",
                "summary": "Harbor Funds, an investment management company, released its Q2 2026 investor letter for “Harbor Mid Cap Value Fund”. The letter can be downloaded here. Global equities experienced a sharp rally in Q2 2026, with the S&P 500 returning 15.2%, its strongest quarter since 2020, driven by a shift from software to hardware in the Artificial Intelligence […]",
                "category": "company",
                "datetime": 1788882100,
                "headline": "Evaluating Bullish Potential in Regeneron Pharmaceuticals (REGN) Stock"
              },
              {
                "id": 141950846,
                "url": "https://finnhub.io/api/news?id=e438ae2c1ce675ea7e9b029214e096bc1178eb10366f039abc942f9300b3246f",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "REGN",
                "summary": "Although Regeneron (currently trading at $845.04 per share) has gained 8.1% over the last six months, it has trailed the S&P 500’s 13.6% return during that period. This may have investors wondering how to approach the situation.",
                "category": "company",
                "datetime": 1788875478,
                "headline": "3 Reasons to Avoid REGN and 1 Stock to Buy Instead"
              },
              {
                "id": 141379966,
                "url": "https://finnhub.io/api/news?id=f63e7df83cb06137446a745912a72d41f1540cf5de8312c3e91893f9a0005a84",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "REGN",
                "summary": "Regeneron Pharmaceuticals has outpaced the healthcare sector, and analysts remain moderately optimistic about the stock’s outlook.",
                "category": "company",
                "datetime": 1788348638,
                "headline": "Regeneron Pharmaceuticals Stock: Is REGN Outperforming the Healthcare Sector?"
              },
              {
                "id": 141362974,
                "url": "https://finnhub.io/api/news?id=98a3e05da90c115be6f04325b4f24cf6df2e70ba582d1cb844a547d7d7c0d245",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "REGN",
                "summary": "Regeneron Pharmaceuticals (REGN) is back in focus after the FDA approved Pasatru garetosmab grts for adults with fibrodysplasia ossificans progressiva, following positive Phase 3 OPTIMA trial data on heterotopic ossification lesion reduction. Regeneron Pharmaceuticals shares trade at US$794.19 after a recent pullback, with the 7 day share price return down 4.78% and the 90 day share price return up 32.22%. The 1 year total shareholder return of 37.47% points to momentum that has built over a...",
                "category": "company",
                "datetime": 1788059730,
                "headline": "Regeneron Pharmaceuticals (REGN) As Pasatru Approval Tests An Undervalued View"
              },
              {
                "id": 141362975,
                "url": "https://finnhub.io/api/news?id=261738a09c9f329cb80f1680273b0fdf7681661866ef5b7ad49676411841b661",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "REGN",
                "summary": "Regeneron Pharmaceuticals (NasdaqGS: REGN) received FDA approval for Pasatru TM (garetosmab grts) to treat adults with fibrodysplasia ossificans progressiva. The approval is based on a positive Phase 3 trial in this rare and severely debilitating condition. Pasatru adds a new rare disease therapy to Regeneron's portfolio and introduces a fresh product-based revenue stream. This kind of targeted drug development in rare diseases is part of a wider shift toward more data driven healthcare,...",
                "category": "company",
                "datetime": 1788038070,
                "headline": "Regeneron Pharmaceuticals (REGN) Wins FDA Approval For Pasatru In Adult FOP"
              },
              {
                "id": 141362976,
                "url": "https://finnhub.io/api/news?id=e7a98de754fd531bdedb24a7df582f052851363596e1136d94736f507ef73172",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "REGN",
                "summary": "The FDA approved Pasatru, whose generic name is garetosmab, of Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) for adults with fibrodysplasia ossificans progressiva. FOP is an ultra-rare genetic disorder in which bone forms inside muscles, tendons, and ligaments, progressively restricting movement. In a 56-week Phase 3 trial involving 63 adults, the approved 3-milligram-per-kilogram dose reduced the number of […]",
                "category": "company",
                "datetime": 1787868250,
                "headline": "Can Regeneron (REGN)’s Rare-Disease Win Move the Earnings Needle?"
              },
              {
                "id": 141362977,
                "url": "https://finnhub.io/api/news?id=1f298f4df61968d45fcb41d4feda958c15568182d6d6f59fa9593c47198bdf22",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "REGN",
                "summary": "Sound Shore Management, an investment management firm, has released its investor letter for the second quarter of 2026. The letter can be downloaded here. The Sound Shore Fund’s Investor Class (SSHFX) and Institutional Class (SSHVX) rose 10.48% and 10.58% in the second quarter of 2026, trailing the Russell 1000 Value Index’s 13.87% and the S&P 500’s […]",
                "category": "company",
                "datetime": 1787838180,
                "headline": "Regeneron Pharmaceuticals (REGN) Adjusts Course Amid Mixed Results in Melanoma Drug Trials"
              },
              {
                "id": 141280298,
                "url": "https://finnhub.io/api/news?id=c11b7e113d90aee4294da1b91ca91359cae764d5f3420ce18f042d740389998d",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "REGN",
                "summary": "In August 2026, Regeneron Pharmaceuticals announced that the US FDA approved Pasatru (garetosmab-grts) to reduce new heterotopic ossification lesions and flare-ups in adults with fibrodysplasia ossificans progressiva, based on positive Phase 3 OPTIMA trial results. This approval adds a rare-disease monoclonal antibody to Regeneron’s portfolio, reinforcing the company’s focus on specialized, high-complexity immunology therapies. We’ll now examine how Pasatru’s FOP approval, as an ultra-rare...",
                "category": "company",
                "datetime": 1787206256,
                "headline": "Why Regeneron (REGN) Is Up 5.4% After FDA Approves Pasatru For Ultra-Rare FOP Therapy"
              }
            ],
            "raw_source": [
              {
                "id": 141950848,
                "url": "https://finnhub.io/api/news?id=025ab8bb5b52548fe73e84956d901e99f64b8a2d0c299eba6338137c0b522450",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "REGN",
                "summary": "Harbor Funds, an investment management company, released its Q2 2026 investor letter for “Harbor Mid Cap Value Fund”. The letter can be downloaded here. Global equities experienced a sharp rally in Q2 2026, with the S&P 500 returning 15.2%, its strongest quarter since 2020, driven by a shift from software to hardware in the Artificial Intelligence […]",
                "category": "company",
                "datetime": 1788882100,
                "headline": "Evaluating Bullish Potential in Regeneron Pharmaceuticals (REGN) Stock"
              },
              {
                "id": 141950171,
                "url": "https://finnhub.io/api/news?id=63b295bab3be0891bf9ee70fd457cef66148a6bda49292db5597d3c12a06706b",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "REGN",
                "summary": "While Wall Street piles into AI darlings, Michael Burry is quietly loading up on call options in three stocks the market left for dead, and his biggest bets carry a very specific thesis about where the crowd got it wrong.",
                "category": "company",
                "datetime": 1788876330,
                "headline": "Big Short Billionaire Goes Long: Michael Burry Avoids AI, Bets on Beaten own Stocks Instead"
              },
              {
                "id": 141950846,
                "url": "https://finnhub.io/api/news?id=e438ae2c1ce675ea7e9b029214e096bc1178eb10366f039abc942f9300b3246f",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "REGN",
                "summary": "Although Regeneron (currently trading at $845.04 per share) has gained 8.1% over the last six months, it has trailed the S&P 500’s 13.6% return during that period. This may have investors wondering how to approach the situation.",
                "category": "company",
                "datetime": 1788875478,
                "headline": "3 Reasons to Avoid REGN and 1 Stock to Buy Instead"
              },
              {
                "id": 141771131,
                "url": "https://finnhub.io/api/news?id=54bd7ced710bb8cc5af628a759507a12394f53b813d5d08ed02199f47fabf0b9",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "REGN",
                "summary": "Biotech just staged one of its sharpest reversals in years, and whether you caught it or completely missed it, the same uncomfortable question now sits in front of every portfolio: does the trade still have teeth, or did the easy money already leave?",
                "category": "company",
                "datetime": 1788798125,
                "headline": "IBB Just Beat the S&P 500 by 22 Points in Three Months. Are You Late to the Party?"
              },
              {
                "id": 141454921,
                "url": "https://finnhub.io/api/news?id=2109b2d0a9fc059644620ec0e33e0c12123ced56d7da3cfb25d8902e87fffdc0",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "REGN",
                "summary": "They could both outperform the market over the medium term, but one appears to have a clear edge.",
                "category": "company",
                "datetime": 1788547800,
                "headline": "Vertex vs. Regeneron: Which Biotech Giant Is the Better Buy Right Now?"
              },
              {
                "id": 141437744,
                "url": "https://finnhub.io/api/news?id=c17ca7a68781b73878487fa544d16378ae1dedade594899c9999fe8515f0a775",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "REGN",
                "summary": "Black Diamond (BDTX) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.",
                "category": "company",
                "datetime": 1788535835,
                "headline": "Black Diamond (BDTX) Up 9.4% Since Last Earnings Report: Can It Continue?"
              },
              {
                "id": 141446631,
                "url": "https://finnhub.io/api/news?id=acc97bf164cbb510d5f95d4dd90bb12e4789e33a92896040efbc52ce5956ac8f",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "REGN",
                "summary": "The drugmaker is leaning on a better side effect profile compared to drugs from J&J, Pfizer and Regeneron as it pushes etentamig toward FDA submission.",
                "category": "company",
                "datetime": 1788523200,
                "headline": "Trailing rivals, AbbVie scores win with dual-acting myeloma drug"
              },
              {
                "id": 141408000,
                "url": "https://finnhub.io/api/news?id=07c91159a0c1171b678e371099f813e89feca5cf4ca2921069e9eddbbf202aeb",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "REGN",
                "summary": "Veeva Systems (NYSE: VEEV) announced that Regeneron and Biogen have adopted its AI powered Vault CRM suite globally. The company also introduced Veeva Falcon Safety, a new agentic safety operations product for biopharma clients. Both moves expand Veeva Systems' AI focused offering across commercial and safety workflows in life sciences. These updates highlight how AI heavy software is becoming core infrastructure for healthcare and biopharma workflows. This connects directly to a wider set...",
                "category": "company",
                "datetime": 1788496719,
                "headline": "Why Is Veeva Systems (VEEV) Winning Big In AI For Biopharma?"
              },
              {
                "id": 141381556,
                "url": "https://finnhub.io/api/news?id=65d8a605fbcff6ce83f3ba9ca5f420fae5aafa164d759a46d222c77b5ff55912",
                "image": "https://cdn.benzinga.com/files/images/story/2025/07/10/valuestock_4.jpg?width=2048&height=1536",
                "source": "Benzinga",
                "related": "REGN",
                "summary": "Regeneron Pharmaceuticals (NASDAQ:REGN) has outperformed the market over the past 15 years by 4.59% on an annualized basis producing an average annual return of 17.79%. Currently, Regeneron Pharmaceuticals has a market",
                "category": "company",
                "datetime": 1788353130,
                "headline": "Here’s How Much You Would Have Made Owning Regeneron Pharmaceuticals Stock In The Last 15 Years"
              },
              {
                "id": 141376579,
                "url": "https://finnhub.io/api/news?id=72293305988b40ef782882dc2e794c33b755d829ee864f33a30ff22cb84aa62a",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "REGN",
                "summary": "Complement Inhibitors Market Complement Inhibitors Market Dublin, Sept. 02, 2026 (GLOBE NEWSWIRE) -- The \"Complement Inhibitors Market (2nd Edition): Distribution by Target Disease Indication, Therapeutic Area, Type of Molecule, Target Pathway, Type of Therapy, Route of Administration, Leading Drugs, Key Geographical Regions and Leading Players - Trends and Forecast Till 2035\" has been added to ResearchAndMarkets.com's offering. The global complement inhibitors market is projected to increase fr",
                "category": "company",
                "datetime": 1788351420,
                "headline": "2026 Complement Inhibitors Market Analysis Report (2nd Edition) Featuring Amgen, CSL Behring, Innovent Biologics, Novartis, Regeneron, Roche, Sanofi, Takeda, UCB"
              },
              {
                "id": 141379966,
                "url": "https://finnhub.io/api/news?id=f63e7df83cb06137446a745912a72d41f1540cf5de8312c3e91893f9a0005a84",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "REGN",
                "summary": "Regeneron Pharmaceuticals has outpaced the healthcare sector, and analysts remain moderately optimistic about the stock’s outlook.",
                "category": "company",
                "datetime": 1788348638,
                "headline": "Regeneron Pharmaceuticals Stock: Is REGN Outperforming the Healthcare Sector?"
              },
              {
                "id": 141356225,
                "url": "https://finnhub.io/api/news?id=59a441525d8351f9ca682906e1f1184af38874463dd1c92a51d84c67a55ae7f7",
                "image": "",
                "source": "SeekingAlpha",
                "related": "REGN",
                "summary": "",
                "category": "company",
                "datetime": 1788188253,
                "headline": "Trump Admin To Target Biotechs With Curbs On Drug Pricing? What Investors Should Know"
              },
              {
                "id": 141355051,
                "url": "https://finnhub.io/api/news?id=d92b169b63df4d431d6ca4d3e2a910e2a44404564eff749693f603b009075ae3",
                "image": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/466613278/image_466613278.jpg?io=getty-c-w1536",
                "source": "SeekingAlpha",
                "related": "REGN",
                "summary": "Big Pharma hits new 52-week highs on strong Q2 results; explore why some lag and which healthcare ETF offers best income risk/reward. Click for more and the picks.",
                "category": "company",
                "datetime": 1788173434,
                "headline": "Big Pharma's Comeback Is Here: Winners, Losers, And 4 ETFs"
              },
              {
                "id": 141361448,
                "url": "https://finnhub.io/api/news?id=247b5f6fb2e792b2b976e2e3c0a3d8dea41e34ecf81ad68e0b96cdb61a1bc71e",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "REGN",
                "summary": "The global non-melanoma skin cancer (NMSC) market is growing as basal cell carcinoma and squamous cell carcinoma rates rise due to UV exposure and aging populations. Advanced diagnostics, AI, targeted therapies, superficial radiation therapy and electronic brachytherapy are improving early detection and outcomes. North America leads the market, followed by Europe, while Asia-Pacific is expanding rapidly. Key players include Amgen, Regeneron, Almirall and Boehringer Ingelheim. FDA-approved Libtay",
                "category": "company",
                "datetime": 1788170580,
                "headline": "Non-Melanoma Skin Cancer Market: Focus on Disease Indication, Treatment Type, Country and Region, 2025-2035"
              },
              {
                "id": 141362974,
                "url": "https://finnhub.io/api/news?id=98a3e05da90c115be6f04325b4f24cf6df2e70ba582d1cb844a547d7d7c0d245",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "REGN",
                "summary": "Regeneron Pharmaceuticals (REGN) is back in focus after the FDA approved Pasatru garetosmab grts for adults with fibrodysplasia ossificans progressiva, following positive Phase 3 OPTIMA trial data on heterotopic ossification lesion reduction. Regeneron Pharmaceuticals shares trade at US$794.19 after a recent pullback, with the 7 day share price return down 4.78% and the 90 day share price return up 32.22%. The 1 year total shareholder return of 37.47% points to momentum that has built over a...",
                "category": "company",
                "datetime": 1788059730,
                "headline": "Regeneron Pharmaceuticals (REGN) As Pasatru Approval Tests An Undervalued View"
              },
              {
                "id": 141362975,
                "url": "https://finnhub.io/api/news?id=261738a09c9f329cb80f1680273b0fdf7681661866ef5b7ad49676411841b661",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "REGN",
                "summary": "Regeneron Pharmaceuticals (NasdaqGS: REGN) received FDA approval for Pasatru TM (garetosmab grts) to treat adults with fibrodysplasia ossificans progressiva. The approval is based on a positive Phase 3 trial in this rare and severely debilitating condition. Pasatru adds a new rare disease therapy to Regeneron's portfolio and introduces a fresh product-based revenue stream. This kind of targeted drug development in rare diseases is part of a wider shift toward more data driven healthcare,...",
                "category": "company",
                "datetime": 1788038070,
                "headline": "Regeneron Pharmaceuticals (REGN) Wins FDA Approval For Pasatru In Adult FOP"
              },
              {
                "id": 141351867,
                "url": "https://finnhub.io/api/news?id=395379d6663c343e569dce43c64437eefbec168da839d902eecead5e207b8ab3",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "REGN",
                "summary": "Sanofi's stock trades above key moving averages as Dupixent and new drugs drive growth, while pipeline setbacks and vaccine weakness weigh.",
                "category": "company",
                "datetime": 1787935500,
                "headline": "SNY Stock Trading Above 50- & 200-Day SMAs: Buy, Hold or Sell?"
              },
              {
                "id": 141338793,
                "url": "https://finnhub.io/api/news?id=bd81a66323ddaec8a6c063ad55e9bab105eb706d36589a0de58b89f58003aded",
                "image": "",
                "source": "Benzinga",
                "related": "REGN",
                "summary": "https://www.who.int/news/item/28-08-2026-second-meeting-of-the-ihr-emergency-committee-on-the-epidemic-of-ebola-bundibugyo-virus-disease-in-the-democratic-republic-of-the-congo---meeting-report",
                "category": "company",
                "datetime": 1787921002,
                "headline": "World Health Organization Director General Determined That The Ebola Epidemic In DRC Still Meets Criteria Of Public Health Emergency Of International Concern, But Not Those Of A Pandemic Emergency"
              },
              {
                "id": 141362976,
                "url": "https://finnhub.io/api/news?id=e7a98de754fd531bdedb24a7df582f052851363596e1136d94736f507ef73172",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "REGN",
                "summary": "The FDA approved Pasatru, whose generic name is garetosmab, of Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) for adults with fibrodysplasia ossificans progressiva. FOP is an ultra-rare genetic disorder in which bone forms inside muscles, tendons, and ligaments, progressively restricting movement. In a 56-week Phase 3 trial involving 63 adults, the approved 3-milligram-per-kilogram dose reduced the number of […]",
                "category": "company",
                "datetime": 1787868250,
                "headline": "Can Regeneron (REGN)’s Rare-Disease Win Move the Earnings Needle?"
              },
              {
                "id": 141351856,
                "url": "https://finnhub.io/api/news?id=f4bb0891bf60431695c3e21ae502bfb3cdd9965ddaacac579d244f8058de09a0",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "REGN",
                "summary": "Amgen and AstraZeneca's drug, Tezspire, scored Thursday in an esophageal disease that affects an estimated 470,000 patients in the U.S.",
                "category": "company",
                "datetime": 1787866152,
                "headline": "Amgen, AstraZeneca Score With Tezspire; Can They Take On Dupixent?"
              },
              {
                "id": 141362977,
                "url": "https://finnhub.io/api/news?id=1f298f4df61968d45fcb41d4feda958c15568182d6d6f59fa9593c47198bdf22",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "REGN",
                "summary": "Sound Shore Management, an investment management firm, has released its investor letter for the second quarter of 2026. The letter can be downloaded here. The Sound Shore Fund’s Investor Class (SSHFX) and Institutional Class (SSHVX) rose 10.48% and 10.58% in the second quarter of 2026, trailing the Russell 1000 Value Index’s 13.87% and the S&P 500’s […]",
                "category": "company",
                "datetime": 1787838180,
                "headline": "Regeneron Pharmaceuticals (REGN) Adjusts Course Amid Mixed Results in Melanoma Drug Trials"
              },
              {
                "id": 141331001,
                "url": "https://finnhub.io/api/news?id=0d21b2f6e3024a44935d9c93f8b3e83678d54aa30f5a1d03f4cbdece76ec937e",
                "image": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/1354562475/image_1354562475.jpg?io=getty-c-w1536",
                "source": "SeekingAlpha",
                "related": "REGN",
                "summary": "Corvus Pharmaceuticals has delivered strong soquelitinib data in atopic dermatitis, driving a significant market rally and a robust cash raise. Learn more about CRVS stock here.",
                "category": "company",
                "datetime": 1787833778,
                "headline": "Corvus Pharmaceuticals: Steady As She Goes With Strong Footing In Atopic Dermatitis Treatment"
              },
              {
                "id": 141329551,
                "url": "https://finnhub.io/api/news?id=320a5de29203b8e44f2edf5548e3915f957e76feed78625c85f5fe1da7b57b64",
                "image": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/2217679967/image_2217679967.jpg?io=getty-c-w1536",
                "source": "SeekingAlpha",
                "related": "REGN",
                "summary": "GSK stock outlook: FDA bepirovirsen Oct 26 decision, Phase 3 OCEAN results, and reaffirmed 2026 guidance. Read here for a detailed investment analysis.",
                "category": "company",
                "datetime": 1787818087,
                "headline": "GSK: Still One Of My Top Healthcare Picks"
              },
              {
                "id": 141329625,
                "url": "https://finnhub.io/api/news?id=95da78f240145b001517572b2bbcf2ef23b024c1059093434d3ab32af2a97dde",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "REGN",
                "summary": "Veeva Systems (NYSE:VEEV) reported fiscal 2027 second-quarter revenue of $928 million and non-GAAP operating income of $416 million, with Chief Executive Officer Peter Gassner saying results exceeded the company’s guidance. Management highlighted record CRM performance, broad commercial-cloud moment",
                "category": "company",
                "datetime": 1787789059,
                "headline": "Veeva Systems Q2 Earnings Call Highlights"
              },
              {
                "id": 141362978,
                "url": "https://finnhub.io/api/news?id=9f6a4ad8b6a32a6c342a890a08e3b574acd3578cb52ffdca8acf6f69eec196b5",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "REGN",
                "summary": "Regeneron Pharmaceuticals has comfortably outperformed the S&P 500 over the past year, and Wall Street remains reasonably bullish on the company’s long-term growth prospects.",
                "category": "company",
                "datetime": 1787749288,
                "headline": "Regeneron Pharmaceuticals Stock Outlook: Is Wall Street Bullish or Bearish?"
              },
              {
                "id": 141329623,
                "url": "https://finnhub.io/api/news?id=fe546552a0c8ef5e8d86a5751f5b4a949d1e90cfe0144073a4836877094a1668",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "REGN",
                "summary": "Veeva Systems' (VEEV) Vault CRM has cemented its position as the clear market leader in life science",
                "category": "company",
                "datetime": 1787687979,
                "headline": "Veeva's Vault CRM Wins Reinforce Market-Leader Status Ahead of Earnings, Truist Says"
              },
              {
                "id": 141362979,
                "url": "https://finnhub.io/api/news?id=bc45e27d9ee942e817e5396bdf9d9ba6158711cb33392cc2c71411ef7604e8ac",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "REGN",
                "summary": "Veeva Systems (NYSE: VEEV) today announced that Regeneron Pharmaceuticals has committed to Veeva Vault CRM globally. With Vault CRM, Regeneron plans to generate Commercial Evidence from AI-powered field engagement, uncovering hidden barriers to treatment adoption and ensuring their medicines can reach eligible patients in need.",
                "category": "company",
                "datetime": 1787659380,
                "headline": "Veeva Vault CRM Selected by Regeneron"
              },
              {
                "id": 141316212,
                "url": "https://finnhub.io/api/news?id=5e6fefaa99fcd424019f11ce4f04ca63d98863c1cd874b1f5971c0ae40aed934",
                "image": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/2230550003/image_2230550003.jpg?io=getty-c-w1536",
                "source": "SeekingAlpha",
                "related": "REGN",
                "summary": "Regeneron Pharmaceuticals, Inc. stock outlook: Eylea pressure eases as Dupixent jumps; FDA OKs Pasatru. Read why REGN stock is a buy.",
                "category": "company",
                "datetime": 1787648487,
                "headline": "Regeneron: Why I Still See Upside After The Rally"
              },
              {
                "id": 141318086,
                "url": "https://finnhub.io/api/news?id=9eb411346c94435d6ecf1d2f8a7863b5cbed1f819ca201437143c429531a7e1a",
                "image": "https://cdn.benzinga.com/files/images/story/2025/07/10/valuestock_4.jpg?width=2048&height=1536",
                "source": "Benzinga",
                "related": "REGN",
                "summary": "Regeneron Pharmaceuticals (NASDAQ:REGN) has outperformed the market over the past 15 years by 6.17% on an annualized basis producing an average annual return of 19.2%. Currently, Regeneron Pharmaceuticals has a market",
                "category": "company",
                "datetime": 1787600747,
                "headline": "$100 Invested In Regeneron Pharmaceuticals 15 Years Ago Would Be Worth This Much Today"
              },
              {
                "id": 141308324,
                "url": "https://finnhub.io/api/news?id=d230e0ece83f4cba236cd869d85db24371c89847d296e0eca3524ccfa078799b",
                "image": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/1419068069/image_1419068069.jpg?io=getty-c-w1536",
                "source": "SeekingAlpha",
                "related": "REGN",
                "summary": "Sanofi stock faces temporary pressure after Trump’s vaccine order, but trades cheap (9.2x P/E) with raised 2026 guidance. Click for this SNY update.",
                "category": "company",
                "datetime": 1787561537,
                "headline": "Sanofi: Trump's Vaccine Policy Won't Break The Story"
              },
              {
                "id": 141280303,
                "url": "https://finnhub.io/api/news?id=f24a65610714776bf40f673b3885f0ae21ce54c8f1848b750da19bfccbe93421",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "REGN",
                "summary": "Oil transportation stock Frontline is at a new high in Friday's stock market. Advantest, Regeneron Pharma and Magna International are also at highs.",
                "category": "company",
                "datetime": 1787344766,
                "headline": "Oil Shipper Hits New High; Three Stocks Also Near Pivots"
              },
              {
                "id": 141280304,
                "url": "https://finnhub.io/api/news?id=3156fe6a5851cdc75cb8412a1222531ab4729f4184757a3044b2026f6e3f4d4c",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "REGN",
                "summary": "Moderna stock surged following positive cancer-vaccine data, burning short sellers and spilling over into the semi sector.",
                "category": "company",
                "datetime": 1787260020,
                "headline": "How Moderna’s Historic Short Squeeze Upended the AI Chip Trade"
              },
              {
                "id": 141265989,
                "url": "https://finnhub.io/api/news?id=1bee81ba5d433236efc3e62ed2865d74d3bf07b3d8070f81fe26133fbf19dfc8",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "REGN",
                "summary": "REGN's Pasatru wins FDA approval for FOP, cutting new HO lesions by 90% or more and reducing clinician-assessed flare-ups.",
                "category": "company",
                "datetime": 1787240160,
                "headline": "Regeneron Secures FDA Approval for Rare Genetic Disorder Drug"
              },
              {
                "id": 141263269,
                "url": "https://finnhub.io/api/news?id=3a7d8b644a95dfa9bef9c6a61af9b2916e3d3f851c8fc89b334aff48a5473f43",
                "image": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/2289951765/image_2289951765.jpg?io=getty-c-w1536",
                "source": "SeekingAlpha",
                "related": "REGN",
                "summary": "Alvotech stock outlook: Hold rating after missed H1 2026 earnings and FDA CRLs; biosimilar pipeline targets Q4 2026. Click for this ALVO update.",
                "category": "company",
                "datetime": 1787235706,
                "headline": "Alvotech: Reiterate Hold On AVT05/AVT06 BLA Resubmissions And Upcoming Catalysts"
              },
              {
                "id": 141280297,
                "url": "https://finnhub.io/api/news?id=15bc209d2431fe27cf96a6134f9ac4121af7e38b6a3765c934dbd1c40118b761",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "REGN",
                "summary": "Pasatru’s approval sets up a market battle in a rare indication where the only available treatment has generated disappointing sales.",
                "category": "company",
                "datetime": 1787232085,
                "headline": "Regeneron to challenge Ipsen as FDA clears bone disease drug"
              },
              {
                "id": 141266464,
                "url": "https://finnhub.io/api/news?id=faf6a41e992a7342b9b3619c09459fdbd23792a308a7ae8f10cf87707f80907d",
                "image": "https://cdn.benzinga.com/files/images/story/2026/08/20/Regeneron.jpg?width=2048&height=1536",
                "source": "Benzinga",
                "related": "REGN",
                "summary": "Regeneron Pharmaceuticals secured FDA approval for Pasatru, a novel monthly infusion therapy proven to reduce lesions in FOP patients.",
                "category": "company",
                "datetime": 1787217922,
                "headline": "Regeneron Secures FDA Approval For Ultra-Rare Bone Disorder Drug"
              },
              {
                "id": 141262712,
                "url": "https://finnhub.io/api/news?id=6182e06fcba5dbc34027eee96f1ed492ce9df1b409353299365a2692025b91dc",
                "image": "https://cdn.benzinga.com/files/images/story/2026/08/20/Investor-Planning-And-Strategy--Stock-Ma.jpg?width=2048&height=1536",
                "source": "Benzinga",
                "related": "REGN",
                "summary": "Bill Ackman gifted $400 million of his Pershing Square stake to a brain research foundation after his daughter's near-fatal hemorrhage.",
                "category": "company",
                "datetime": 1787207626,
                "headline": "Bill Ackman Donates $400 Million in Pershing Square Stock to Build a Research Institute After His Daughter’s Severe Brain Hemorrhage"
              },
              {
                "id": 141280298,
                "url": "https://finnhub.io/api/news?id=c11b7e113d90aee4294da1b91ca91359cae764d5f3420ce18f042d740389998d",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "REGN",
                "summary": "In August 2026, Regeneron Pharmaceuticals announced that the US FDA approved Pasatru (garetosmab-grts) to reduce new heterotopic ossification lesions and flare-ups in adults with fibrodysplasia ossificans progressiva, based on positive Phase 3 OPTIMA trial results. This approval adds a rare-disease monoclonal antibody to Regeneron’s portfolio, reinforcing the company’s focus on specialized, high-complexity immunology therapies. We’ll now examine how Pasatru’s FOP approval, as an ultra-rare...",
                "category": "company",
                "datetime": 1787206256,
                "headline": "Why Regeneron (REGN) Is Up 5.4% After FDA Approves Pasatru For Ultra-Rare FOP Therapy"
              },
              {
                "id": 141280305,
                "url": "https://finnhub.io/api/news?id=22242cefabb7c1091c3a38e228009d5220ab46b19b1c00ec1016de4d84fde03d",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "REGN",
                "summary": "Regeneron Pharmaceuticals stock has delivered a 43.0% return over the past year, yet the broader valuation checks point to a more mixed picture rather than a clear bargain or obvious overpricing. With recent partnership activity and pipeline progress in the spotlight, investors are weighing how much of that is already reflected in the current US$840.84 share price. The 43.0% one year return signals that the market has already repriced Regeneron Pharmaceuticals positively. The key issue for...",
                "category": "company",
                "datetime": 1787203721,
                "headline": "Regeneron (REGN) Stock Looks Undervalued On Expanded Cancer Collaboration News"
              },
              {
                "id": 141280306,
                "url": "https://finnhub.io/api/news?id=5083f99f94224d2fcc197523c6ed51177064d74a92f3d5485a71185525abf6a0",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "REGN",
                "summary": "Telix Pharmaceuticals Limited (ASX: TLX, NASDAQ: TLX, \"Telix\") today announces its financial results for the period ended June 30, 2026.",
                "category": "company",
                "datetime": 1787187720,
                "headline": "Telix 2026 Half-Year Results: Strong Commercial Execution and Momentum in Late-Stage Pipeline"
              },
              {
                "id": 141280307,
                "url": "https://finnhub.io/api/news?id=536cb62d7b3f3dc020abb5a4932c6fad2c3b1062725c8f79313b81f51bcd8514",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "REGN",
                "summary": "TARRYTOWN, N.Y., Aug. 19, 2026 (GLOBE NEWSWIRE) -- Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) will webcast management participation as follows: 2026 Wells Fargo Healthcare Conference at 8:45 a.m. ET on Wednesday, September 9, 2026Morgan Stanley 24th Annual Global Healthcare Conference at 1:05 p.m. ET on Monday, September 14, 2026Bernstein Insights: Healthcare Leaders and Disruptors – 3rd Annual Healthcare Forum at 10:30 a.m. ET on Wednesday, September 23, 2026 The sessions may be accessed fr",
                "category": "company",
                "datetime": 1787173500,
                "headline": "Regeneron Announces Investor Conference Presentations"
              },
              {
                "id": 141280299,
                "url": "https://finnhub.io/api/news?id=3bd2e304a2025ec73855791390cca0ba4e69e8c7ef135572cce977978a4f21e1",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "REGN",
                "summary": "FOP is an ultra-rare genetic disorder characterized by rogue bone formation that infiltrates muscles, tendons, ligaments and other connective tissues, resulting in significant disability Approval based on results from the OPTIMA trial demonstrating a 90% or greater reduction in new HO lesions at 56 weeks with a dramatic reduction in clinician-assessed flare-ups in adults with FOP TARRYTOWN, N.Y., Aug. 19, 2026 (GLOBE NEWSWIRE) -- Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) today announced the",
                "category": "company",
                "datetime": 1787165880,
                "headline": "Pasatru™ (garetosmab-grts) First and Only FDA-approved Treatment Demonstrating Reduction in New Heterotopic Ossification (HO) Lesions and Clinician-Assessed Flare-ups in a Placebo-controlled Trial in Adults with Fibrodysplasia Ossificans Progressiva (FOP)"
              },
              {
                "id": 141280308,
                "url": "https://finnhub.io/api/news?id=7225a1a6352720c9cac42b9d4ce47631a603318f17a881592aeb516dac788b79",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "REGN",
                "summary": "OPKO Health pairs a discounted forward sales multiple with narrowing losses and partnership support, but early-stage clinical risk keeps the investment case balanced.",
                "category": "company",
                "datetime": 1787161200,
                "headline": "Is OPK Worth Buying as Valuation Meets Improving Business Trends?"
              },
              {
                "id": 141278143,
                "url": "https://finnhub.io/api/news?id=1d3df2215833561fd1be2c6edc2abe71630998ac9a6498e48a23e158b2a81595",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "REGN",
                "summary": "Teva's stock gains reflect stronger branded drug growth, a strengthening pipeline and improving finances, but generics and debt remain key risks.",
                "category": "company",
                "datetime": 1787155560,
                "headline": "Teva Rises 17% YTD: Should You Buy, Sell or Hold the Stock?"
              },
              {
                "id": 141278987,
                "url": "https://finnhub.io/api/news?id=c97b2ccd97ddfa672c60e63652ba2e8437994be90f671596a70688e6b4a7bd42",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "REGN",
                "summary": "Franklin Biotechnology Discovery has a much higher 13% five-year annualized return than a biotech index ETF’s 5.3%",
                "category": "company",
                "datetime": 1787154240,
                "headline": "Biotech Stocks Are Booming. What This Top Fund Is Buying Now."
              },
              {
                "id": 141256304,
                "url": "https://finnhub.io/api/news?id=d7c8b54d1f562cc1f7872fbb1f6bff62124bb24d7d7f462e899240562823c619",
                "image": "",
                "source": "Benzinga",
                "related": "REGN",
                "summary": "Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) today announced the U.S. Food and Drug Administration (FDA) has granted approval for Pasatru™ (garetosmab-grts) to reduce formation of new heterotopic ossification (HO)",
                "category": "company",
                "datetime": 1787148138,
                "headline": "Regeneron Pharmaceuticals Granted FDA Approval For Pasatru To Lower Formation Of New Heterotopic Ossification Lesions And Clinician-Assessed Flare-Ups In Adults With Fibrodysplasia Ossificans Progressiva"
              },
              {
                "id": 141265012,
                "url": "https://finnhub.io/api/news?id=6306299bf8c0083ad7ed7398a1dda29d79bf659716d1cdeed57bf18c43632e5c",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "REGN",
                "summary": "Pentavere advances from winning the 2024 Prix Galien USA Award to competing internationally among Prix Galien winners from around the world, further validating DARWEN™ AI as a globally recognized healthcare AI platformThe broader 2026 International Prix Galien nominee field includes innovations from many of the world's leading pharmaceutical, biotechnology and medical technology companies, including AstraZeneca, Merck & Co. (MSD), Johnson & Johnson, Pfizer, Sanofi, Regeneron, Roche, Novo...",
                "category": "company",
                "datetime": 1787139000,
                "headline": "HEALWELL AI's DARWEN(TM) AI Platform Nominated for 2026 International Prix Galien, the Global \"Best of the Best\" in Life Sciences Innovation"
              },
              {
                "id": 141253313,
                "url": "https://finnhub.io/api/news?id=2e1130e90380ab9807504bf240b0038a51a19924cdacc932dd13f4834b335bfb",
                "image": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/1688769969/image_1688769969.jpg?io=getty-c-w1536",
                "source": "SeekingAlpha",
                "related": "REGN",
                "summary": "Rumors of an AstraZeneca PLC-Bristol-Myers Squibb Company merger are cooling. Click here for risks and drug portfolio insights on BMY and AZN stock.",
                "category": "company",
                "datetime": 1787131330,
                "headline": "AstraZeneca Vs. Bristol-Myers Squibb: Who's The Better Bargain For Investors?"
              },
              {
                "id": 141280311,
                "url": "https://finnhub.io/api/news?id=e8004c7a06c56647a03f0ece99f01f1d39b2be91f2b0c3c917cb0353a5e08fd0",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "REGN",
                "summary": "GlobalData highlighted EyePoint’s Duravyu as a notable drug set to enter the wet AMD market by 2034.",
                "category": "company",
                "datetime": 1787067610,
                "headline": "EyePoint’s Duravyu falls short to Eylea in Phase III trial"
              },
              {
                "id": 141265998,
                "url": "https://finnhub.io/api/news?id=3844cefb227a274836745ba85bf678b11c9d8feda43c5123787aaf986a067a08",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "REGN",
                "summary": "EyePoint's Duravyu misses the phase III wet AMD study's primary goal, sending shares down 67%, but shows lower treatment burden and durable disease control.",
                "category": "company",
                "datetime": 1787067180,
                "headline": "EYPT Stock Plunges 67% After Duravyu Misses Phase III Eye Disease Goal"
              },
              {
                "id": 141247393,
                "url": "https://finnhub.io/api/news?id=d98609cacbbd4a08159e7bd82711b940086ebba59ce448ff34d38d20d40ef79a",
                "image": "https://cdn.benzinga.com/files/images/story/2026/08/18/Gentilly--France--March-21--2021-Sign-An.jpg?width=2048&height=1536",
                "source": "Benzinga",
                "related": "REGN",
                "summary": "Sanofi withdrew its Dupixent application for bullous pemphigoid on June 24, 2026, due to unresolved clinical trial limitations.",
                "category": "company",
                "datetime": 1787049992,
                "headline": "European Medicines Agency Concerns Prompt Sanofi To Pull Dupixent Indication"
              },
              {
                "id": 141280312,
                "url": "https://finnhub.io/api/news?id=2fb6d85bc9922eb88449f5679554f34ce15ac2d500aef56b12eb77b308b41744",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "REGN",
                "summary": "Duravyu, EyePoint’s candidate for wet age-related macular degeneration, misses the mark, but muddled trial data may be to blame.",
                "category": "company",
                "datetime": 1786995420,
                "headline": "EyePoint Stock Craters 69% After Drug Trial Failure. It May Be an Overreaction."
              },
              {
                "id": 141280313,
                "url": "https://finnhub.io/api/news?id=5765291ee342fba70b3703ae2a8be1ff36421680e501e331b2c448713ddaae6c",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "REGN",
                "summary": "They are fairly risky, but their potential upside is massive.",
                "category": "company",
                "datetime": 1786915200,
                "headline": "2 GLP-1 Stocks That Could Double Your Money by 2031"
              },
              {
                "id": 141280314,
                "url": "https://finnhub.io/api/news?id=3c05d00bc837232506c304990ace634b5c52ad0b48e6e29356185b5194fe51b0",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "REGN",
                "summary": "They are way more than just GLP-1 stocks.",
                "category": "company",
                "datetime": 1786751400,
                "headline": "GLP-1 Demand Is Soaring. 2 Stocks That Could Benefit From This (Hint: Not Eli Lilly or Novo Nordisk)"
              },
              {
                "id": 141280301,
                "url": "https://finnhub.io/api/news?id=d0ddcf302a5d4a55d81d06ab52de3ce3a18a566e1c12da42f52ab88d1223cda1",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "REGN",
                "summary": "Two prominent biopharmaceutical names, Biohaven Ltd. (NYSE:BHVN) and Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN), are deepening their relationship across oncology. On July 20, Biohaven announced a clinical supply agreement with Regeneron to evaluate the combination of BHV-1530 and Regeneron’s cemiplimab (Libtayo) in patients with solid tumors. BHV-1530’s novel topoisomerase I (TopoIx) payload generates immunogenic cell death and […]",
                "category": "company",
                "datetime": 1786749832,
                "headline": "Is Biohaven (BHVN)’s Latest Regeneron Pharmaceuticals (REGN) Deal a Major Catalyst for its Pipeline?"
              },
              {
                "id": 141218125,
                "url": "https://finnhub.io/api/news?id=343266a2ab01d309b98a829686f38986221f1cda38a9702571e22fe231634d38",
                "image": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/2289244172/image_2289244172.jpg?io=getty-c-w1536",
                "source": "SeekingAlpha",
                "related": "REGN",
                "summary": "Nektar Therapeutics earns a Strong Buy on REZPEG Phase 3 AD/AA upside, $1.02B cash runway to 2028, and big market opportunity. Click for this NKTR update.",
                "category": "company",
                "datetime": 1786717366,
                "headline": "Nektar: Maintaining 'Strong Buy' Rating Due To REZPEG Catalyst, Another Coming"
              },
              {
                "id": 141221146,
                "url": "https://finnhub.io/api/news?id=933949d29f72127befa735f1cb2072ff9e5af6ab396e9b33627d7380cb2018ef",
                "image": "https://cdn.benzinga.com/files/images/story/2025/07/10/valuestock_1.jpg?width=2048&height=1536",
                "source": "Benzinga",
                "related": "REGN",
                "summary": "Regeneron Pharmaceuticals (NASDAQ:REGN) has outperformed the market over the past 20 years by 12.69% on an annualized basis producing an average annual return of 22.03%. Currently, Regeneron Pharmaceuticals has a market",
                "category": "company",
                "datetime": 1786709722,
                "headline": "If You Invested $1000 In Regeneron Pharmaceuticals Stock 20 Years Ago, You Would Have This Much Today"
              },
              {
                "id": 141204834,
                "url": "https://finnhub.io/api/news?id=d32311402b087bec1b3999fc994ac91311c86ee1bb147c22b7585554e17cb2bd",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "REGN",
                "summary": "Advanced zolucatetide across multiple Wnt/β-catenin-driven diseases, including progress toward planned Phase 3 registrational trial in desmoid tumors Announced strategic research collaboration with Regeneron to develop Antibody-Helicon Conjugates, expanding application of company's proprietary HeliconTM platform; received $125M in upfront consideration and equity investment, with the potential for up to $2.2B in milestone payments plus tiered royalties Ended the second quarter with a strong fina",
                "category": "company",
                "datetime": 1786618800,
                "headline": "Parabilis Medicines Reports Second Quarter 2026 Financial Results and Provides Business Updates"
              },
              {
                "id": 141206330,
                "url": "https://finnhub.io/api/news?id=b48a49126c69ae7754badde85bb6d7fde33ff1c2762086ba9e2bc250215c8ab7",
                "image": "https://cdn.benzinga.com/files/images/story/2026/08/13/3d-Rendering-Of-A-Red-Medical-Capsule-An.jpg?width=2048&height=1536",
                "source": "Benzinga",
                "related": "REGN",
                "summary": "China’s science surge is reshaping global drug development as Washington moves to counter Beijing’s growing influence in medicine.",
                "category": "company",
                "datetime": 1786574462,
                "headline": "Big Pharma's Future Growth Rests on Chinese Science? Expert Says: 'We Can't Ban Our Way Out of This'"
              },
              {
                "id": 141200787,
                "url": "https://finnhub.io/api/news?id=dc3dab3edc03595ab00bd23d4c6ee2793a5d03d6fd4f5335c0fe061e120f92cc",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "REGN",
                "summary": "Infinimmune is targeting first-in-human studies with its longer-lasting monoclonal antibodies in 2027.",
                "category": "company",
                "datetime": 1786533370,
                "headline": "Infinimmune raises $75m with big pharma backing for atopic dermatitis drugs"
              },
              {
                "id": 141195501,
                "url": "https://finnhub.io/api/news?id=19d4208c1549cdef413ce3be9fb119601b459b6838a10dc17c6d9e75fb6e10ca",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "REGN",
                "summary": "Regeneron's Eylea HD and Dupixent strength are fueling growth, while oncology gains and pipeline progress support its outlook.",
                "category": "company",
                "datetime": 1786458600,
                "headline": "REGN Soars 21.9% in a Month: Buy, Sell or Hold the Stock?"
              },
              {
                "id": 141184457,
                "url": "https://finnhub.io/api/news?id=41a082b7d0aa667533f2bd4bf66269cd06c65559dacd538bfd979a529a3b8155",
                "image": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/2288287120/image_2288287120.jpg?io=getty-c-w1536",
                "source": "SeekingAlpha",
                "related": "REGN",
                "summary": "U.S. equities posted double-digit quarterly gains despite volatility stemming from the Iran conflict. Read more here.",
                "category": "company",
                "datetime": 1786440600,
                "headline": "American Century Focused Dynamic Growth Fund Q2 2026 Portfolio Review"
              }
            ],
            "data_source": "finnhub_news_keyword_model",
            "article_count": 8,
            "negative_hits": 0,
            "positive_hits": 0,
            "recomputed_at_score": true,
            "sentiment_score_raw": 0,
            "source_article_count": 62,
            "discarded_article_count": 51
          },
          "sentimentPoints": 2
        }
      },
      "技術信號": {
        "max": 30,
        "raw": 18.3,
        "grade": "一般",
        "items": {
          "bbPoints": 2.4,
          "adxPoints": 3,
          "sarPoints": 2.4000000000000004,
          "vcpPoints": 1,
          "macdPoints": 2.4,
          "vcpPayload": {
            "vcp_pass": false,
            "vcp_score": 1,
            "vcp_reason": "跌縮量(近10日4日)；站上MA50；Ready=N；Confirm=N",
            "vcp_metrics": {
              "up_days": 4,
              "vol_ref": 757453.3333333334,
              "down_days": 5,
              "vcp_ready": false,
              "above_ma50": true,
              "avg_vol_10": 640060,
              "avg_vol_20": 685885,
              "avg_vol_30": 757453.3333333334,
              "range_pct_10": 0.09904852834100525,
              "range_pct_20": 0.10305933531611355,
              "range_pct_30": 0.24658464044624892,
              "up_expand_ok": false,
              "lookback_used": 59,
              "near_20d_high": true,
              "contraction_ok": false,
              "down_shrink_ok": true,
              "up_expand_days": 1,
              "breakout_20d_ok": false,
              "vol_ratio_10_30": 0.8450157545459346,
              "dist_to_20d_high": 0.057055447539200534,
              "down_shrink_days": 4,
              "breakout_level_20d": 859.34003,
              "vcp_breakout_confirm": false,
              "contraction_ratio_10_30": 0.40168166257945037
            },
            "vcp_name_en": "Volatility Contraction Pattern",
            "vcp_name_zh": "波動收縮形態",
            "vol_contraction": false
          },
          "kdjAdxPoints": 0.5,
          "rsiKdjPoints": 2.4,
          "volumeWeight": 2,
          "maCrossPoints": 1.6,
          "shortRsiPoints": 0.8,
          "shortMacdPoints": 0.4,
          "volConfirmPoints": 0.6,
          "volumePointsTechnical": 0.8
        }
      },
      "風險管理": {
        "max": 10,
        "grade": "一般",
        "items": {
          "position": {
            "score": 1.6,
            "details": {
              "atrPct": 2.6244770519924474,
              "turnoverUsdM": 447.56662539999996,
              "liquidityPoints": 0.6,
              "volatilityPoints": 1
            }
          },
          "rrPoints": 1.4,
          "stopLevels": {
            "symbol": "US.REGN",
            "rr_range": "1:1.0-1:2.5",
            "risk_profile": "中等",
            "stop_loss_price": 767.7772,
            "strength_details": {
              "ma_score": 1.5,
              "atr_score": 2,
              "rsi_score": 2,
              "macd_score": 1.5,
              "volume_score": 1
            },
            "market_adjustment": 1,
            "risk_reward_ratio": 1,
            "stop_loss_percent": 5.2,
            "take_profit_price": 852.7365,
            "target_multiplier": 1.9,
            "technical_strength": 1.58,
            "take_profit_percent": 5.2
          },
          "positionPoints": 1.6,
          "stopLossPoints": 1.8,
          "diversification": {
            "score": 2,
            "details": {
              "method": "sector concentration proxy; no portfolio holdings used",
              "sector": "Health Care",
              "concentratedSectorPenalty": 0
            }
          },
          "riskRewardRatio": 1.2,
          "stopLossPercent": 5.248954103984895,
          "diversificationPoints": 2
        }
      }
    }
  },
  "modelVersion": "cursor_18_27_news_v2_160",
  "providerErrors": [],
  "rankingScoreMax": 160,
  "dataCompleteness": {
    "complete": true,
    "missingFields": [],
    "optionalInputs": [
      "institutionalData"
    ],
    "requiredInputs": [
      "fundamentals",
      "marketContext.VIX",
      "marketContext.SPY",
      "marketContext.QQQ",
      "catalystData",
      "sentimentData",
      "ATR",
      "sector"
    ],
    "optionalInputWarnings": []
  },
  "technicalIndicators": {
    "adx": 92.86,
    "atr": {
      "atr": 21.2664,
      "rule": "ATR / current price; lower volatility scores higher",
      "score": 6,
      "atr_pct": 2.62
    },
    "cci": {
      "rule": "Cursor_18.24 CCI bands",
      "level": "弱勢",
      "score": 4,
      "value": -34.08
    },
    "cmf": {
      "rule": "Cursor_18.24 CMF bands",
      "level": "派發",
      "score": 2,
      "value": -0.0506
    },
    "kdj": {
      "d": 59.24,
      "j": 51.78,
      "k": 56.75,
      "rule": "Cursor_18.24 K/D cross",
      "score": 0,
      "signal": "死叉"
    },
    "mfi": {
      "rule": "Cursor_18.24 MFI bands",
      "level": "弱流入",
      "score": 4,
      "value": 44.31
    },
    "obv": {
      "rule": "Cursor_18.24 recent_slope vs previous_slope",
      "score": 4,
      "trend": "弱勢",
      "value": 15442760,
      "recentSlope": -112334,
      "previousSlope": 295370
    },
    "rsi": 50.02,
    "sar": {
      "rule": "Cursor_18.24 Parabolic SAR",
      "score": 8,
      "trend": "上升",
      "value": 786.7624,
      "position": "SAR喺價下",
      "distancePct": 2.91,
      "previousTrend": "上升"
    },
    "ma50": 741.4102,
    "macd": {
      "macd": 22.946215400673168,
      "trend": "中性偏多",
      "signal": 28.032036670145107,
      "histogram": -5.085821269471939
    },
    "vwap": {
      "rule": "Cursor_18.24 VWAP 20D consecutive close",
      "score": 2,
      "value": 817.4625,
      "position": "<VWAP",
      "consecutiveAbove": 0
    },
    "volume": {
      "rule": "Cursor_18.24 volume ratio",
      "level": "無力",
      "ratio": 0.85,
      "score": 4,
      "avgVolume": 652817,
      "currentVolume": 552340
    },
    "derived": {
      "ma20": 817.8655,
      "ma50": 741.4102,
      "prevClose": 827.72,
      "avgVolume10": 628094,
      "avgVolume20": 652817,
      "changePercent": -2.1,
      "avgVolumeForScore": 652817
    },
    "ma_cross": {
      "ma20": 817.8655,
      "ma50": 741.4102,
      "rule": "Cursor_18.24 MA20/MA50 cross",
      "cross": "多頭",
      "score": 4,
      "prevMa20": 817.7525,
      "prevMa50": 737.862,
      "spreadPct": 10.31,
      "isVolumeBreakout": false
    },
    "bollinger": {
      "lower": 784.2686,
      "upper": 851.4624,
      "position": "中間"
    },
    "rsi_short": 58.1,
    "macd_short": {
      "macd": 0,
      "trend": "中性",
      "signal": 0,
      "histogram": 0
    },
    "volume_ratio": {
      "ratio": 0.85
    }
  }
}

{
  "close": 810.31,
  "volume": 552340,
  "changePercent": -2.1
}